ArticleScientific reports2026
Prevalence and determinants of secondary hyperparathyroidism: IMOS-2021.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary hyperparathyroidism (SHPT) is a common endocrine disorder among older adults, linked to adverse bone and cardiovascular outcomes. Despite its clinical significance, population-based data on SHPT prevalence and determinants, especially in Middle Eastern thancountries, including Iran, remain scarce. Identifying modifiable and non-modifiable risk factors is critical for targeted prevention and management strategies. This cross-sectional study analyzed data from the Iranian Multicenter Osteoporosis Study (IMOS-2021), a nationally representative cohort of adults aged ≥ 50 years. The weighted prevalence of SHPT was estimated in the 1369 participants. After excluding individuals with possible primary hyperparathyroidism, low PTH, and unknown elevated PTH, participants with SHPT were compared to those with normal PTH regarding demographic, biochemical, and clinical characteristics. Multivariable logistic regression identified independent determinants of SHPT, while linear regression assessed factors influencing serum parathyroid hormone (PTH) levels. The prevalence of SHPT was 12.34% (10.49-14.46). Compared to normal participants (n = 1161), individuals with SHPT (n = 174) had higher body mass index (29.7 vs. 28.0 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.